SLN

Silence Therapeutics PLC

SLN.US silence-therapeutics.com
12.86
-0.16 (-1.23%)
USD · NASDAQ
52-week range
4.19
17.58
Trading at 65% of the 52-week range
Market Cap
809.25M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.81
Div. Yield
N/A
% Institutions
39.68%
% Insiders
7.97%

1 Year

+166.8%

3 Year

+39.3%

10 Year

-33.2%
Description

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Company Information

Company Name
Silence Therapeutics PLC
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US82686Q1013
CIK: 0001479615
CUSIP: 82686Q101
Currency: USD
Full Time Employees: 88
Phone: 44 20 3457 6900
Fiscal Year End: December
IPO Date: Sep 08, 2020
Description:

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Address:

12 Hammersmith Grove, London, United Kingdom, W6 7AP

People

Directors & Officers

Name Title Year Born
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D Interim CEO & Chairman of the Board 1954
Ms. Rhonda L. Hellums Executive VP, CFO, Secretary & Executive Director 1971
Dr. Steven J. Romano M.D. Executive VP and Chief Research & Development Officer 1959
Dr. Marie Wikstrom Lindholm Ph.D. Chief Scientific Officer NA
Ms. Gem Gokmen Hopkins Head of IR & Corporate Communications NA
Mr. Jaimin B. Shah SVP & General Counsel NA
Mr. J.P. Gabriel Chief Technical Operations Officer NA
Mr. Curtis Rambaran M.D. Chief Medical Officer NA

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
TCG Crossover Management, LLC 3.03M Jun 30, 2026 4.88% $0.80 0.00%
Siren, L.L.C. 2.91M Mar 31, 2026 4.68% $0.43 0.00%
Redmile Group, LLC 2.16M Jun 30, 2026 3.48% $1.60 0.00%
Nantahala Capital Management, LLC 2.15M Mar 31, 2026 3.45% $0.42 39.18%
Citadel Advisors Llc 1.33M Jun 30, 2026 2.14% $0.00 7.68%
Nextech Invest, Ltd. 952.40K Jun 30, 2026 1.53% $0.50 0.00%
Millennium Management LLC 909.28K Jun 30, 2026 1.46% $0.00 -15.35%
Ikarian Capital, LLC 865.78K Mar 31, 2026 1.39% $0.14 0.00%
Polygon Management Ltd 764.26K Jun 30, 2026 1.23% $1.32 21.28%
Soleus Capital Management, L.P. 630.00K Jun 30, 2026 1.01% $0.24 0.00%
5AM Venture Management, LLC 476.20K Jun 30, 2026 0.77% $1.82 0.00%
Great Point Partners LLC 450.00K Jun 30, 2026 0.72% $0.93 -55.90%
SG Americas Securities, LLC 286.70K Mar 31, 2026 0.46% $0.00 11.84%
UBS Group AG 246.94K Mar 31, 2026 0.40% $0.00 19.00%
BOOTHBAY FUND MANAGEMENT, LLC 209.09K Mar 31, 2026 0.34% $0.01 0.00%
BlackRock Inc 204.78K Mar 31, 2026 0.33% $0.00 179.93%
BMO Capital Markets Corp. 202.90K Mar 31, 2026 0.33% $0.00 26.44%
Bank of Montreal 201.73K Jun 30, 2026 0.32% $0.00 -0.58%
Propel Bio Management LLC 191.73K Jun 30, 2026 0.31% $1.10 0.00%
ADAR1 Capital Management LLC 172.16K Mar 31, 2026 0.28% $0.05 628.15%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 International Biotechnology Ord 729.62K 1.17% ▲ 0.00% May 31, 2026
2 MEDICAL BioHealth EUR Acc 543.63K 0.87% ▲ 0.09% Jul 31, 2026
3 Fidelity Advisor Biotechnology I 482.09K 0.78% ▲ 0.00% Jul 31, 2026
4 apo Medical Opportunities R 245.19K 0.39% ▲ 0.00% Jul 31, 2026
5 iShares Biotechnology ETF 234.01K 0.38% ▲ 20.19% Aug 31, 2026
6 Alger Life Sciences Innovation Composite 114.95K 0.18% ▲ 0.00% Jun 30, 2026
7 Fidelity Select Biotechnology 103.91K 0.17% ▲ 0.00% Jul 31, 2026
8 RIM Global Bioscience EUR 101.06K 0.16% ▲ 0.00% May 31, 2026
9 Galileo - Biotech Innovation Fund S USD 58.65K 0.09% ▲ 0.00% Feb 28, 2026
10 WEALTHGATE Biotech Fund Inst 38.33K 0.06% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $809.25M
EBITDA: $-63.94M
Book Value: $0.81
Earnings/Share: $-1.29
Profit Margin: 0.00%
Operating Margin: -10,475.61%
ROA (TTM): -29.65%
ROE (TTM): -90.41%
Revenue (TTM): $615.00K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 197.20%

Valuation Metrics

Enterprise Value: $953.60M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 62.15M
Shares Float: 37.84M
% Insiders: 7.97%
% Institutions: 39.68%
Short % Float: 4.81%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$559.00K
Cost of Goods Sold
adjust
$-215.00K
Gross Profit
subtotal
$344.00K
SG&A
adjust
$-22.34M
R&D
adjust
$-67.75M
Operating Income
subtotal
$-89.75M
Other / Non-Operating Items
adjust
$1.14M
Net Income
subtotal
$-88.61M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SLN.US!